You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Vaccine Strategies for Candidal Infections

    SBC: NOVADIGM THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Candida is a fungus that is among the most common causes of infections in hospitalized patients in the United States and worldwide. Candida spp. are one of the most common microbes that infect the blood and urine of hospitalized patients. The cost associated with Candida blood infections alone exceeds at least $1 billion per year in the US. Even with therapy, 4 ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Vaccine-enhanced DLI to prevent cancer recurrence after stem cell transplantation

    SBC: CERUS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Delayed reconstitution of antigen-specific immunity following allogeneic hematopoietic stem cell transplantation (HSCT) predisposes patients to opportunistic infections and tumor recurrence. To address these problems, we are developing a vaccination methodology using a non-replicating but highly immunogenic Listeria monocytogenes (Lm) vector. When an Lm vaccine ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  3. Ultraviolet-C Therapy for Onychomycosis

    SBC: KERADERM, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Keraderm LLC and the Wellman Center for Phototherapy propose a radically new treatment for onychomycosis using germicidal radiation instead of current medications which have significant drawbacks. Onychomycosis is a fungal nail infection that affects approximately 30 million Americans. Americans spend more than $1 Billion per year to treat this problem. However ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. The Mental Health Assessment and Dynamic Referral for Oncology (MHADRO)

    SBC: POLARIS HEALTH DIRECTIONS, INC            Topic: N/A

    DESCRIPTION (provided by applicant): According to the American Cancer Society, approximately 1.3 million people are diagnosed with cancer each year, with the annual cost of treating cancer exceeding $60.9 billion. Mental health and psychosocial factors can be strongly associated with treatment adherence, treatment response, and quality of life among cancer patients. Too often, however, these aspec ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  5. The Dynamic Assessment and Referral System for Substance Abuse (DARSSA)

    SBC: POLARIS HEALTH DIRECTIONS, INC            Topic: N/A

    DESCRIPTION (provided by applicant): The majority of healthcare providers do not routinely screen, counsel, or refer patients who use or abuse tobacco, alcohol, or illicit drugs, despite the dissemination of numerous guidelines recommending such practices. This is a significant problem with far-reaching consequences, including excess morbidity, premature mortality, and inflated healthcare costs ar ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Tendrils: A Multimedia Intervention for Women's Sexual Dysfunction after Cancer

    SBC: Digital Science Technologies LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Long-term Objectives Aims: Sexual dysfunction is the most common long-term consequence of cancer treatment, affecting half of survivors of breast and gynecological cancer and many women treated for other cancers. Yet, few women get the help they need for sexual problems. Our primary objective is to develop and evaluate a multimedia intervention program for wome ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  7. Study of CdZnTe Electrode Interface and Fabrication Technology Development

    SBC: Aguila Technologies, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): In several recent PA's, the NIH has articulated a clear vision for the future of medical imaging systems a) enhanced spatial or temporal resolution, b) better sensitivity and specificity, c) multi-modality, and d) new functional or molecular imaging or spectroscopy methods. Owing to their unique combination of properties, direct conversion gamma radiation imagi ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  8. SoundTrak Data Acquisition and Analysis System for OSDB

    SBC: BARRON ASSOCIATES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Snoring, a symptom of increased upper airway resistance during sleep, is extremely common in children. Such obstructive sleep disordered breathing (OSDB) is now recognized as having substantial neurocognitive, neurobehavioral, and cardiovascular consequences. One of the major limitations in diagnosing OSDB is the need for relatively complex, burdensome, and cos ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  9. Safety of intraarticular N-acetylglucosamine

    SBC: ARTYX PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the most prevalent joint disease, causing joint pain and dysfunction. OA is also associated with substantial co-morbidity and reduces life expectancy. Pharmacologic therapy is limited to symptom modification and disease-modifying therapies are currently not available. Furthermore, even symptom-modifying therapies are limited in efficacy a ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. Safety of A2A Adenosine Agonist for Treatment of Sepsis

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): ATL146e is a synthetic small molecule developed by Adenosine Therapeutics, LLC (ATL) that acts as a selective agonist of the adenosine A2A receptor. ATL146e, sterile solution for intravenous (i.v.) bolus injection, is currently in Phase III of clinical development for use as a coronary vasodilator in pharmacodynamic stress imaging. ATL146e, when administered pa ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government